Stem definition | Drug id | CAS RN |
---|---|---|
1312 | 70-18-8 |
None
None
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hepatic function abnormal | 56.69 | 25.76 | 23 | 1139 | 32658 | 50571304 |
Drug-induced liver injury | 36.12 | 25.76 | 16 | 1146 | 28079 | 50575883 |
Eosinophilic pneumonia chronic | 30.65 | 25.76 | 5 | 1157 | 170 | 50603792 |
Bowel movement irregularity | 27.92 | 25.76 | 8 | 1154 | 3960 | 50600002 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hepatic function abnormal | 66.86 | 31.18 | 31 | 1023 | 39228 | 29534245 |
Lymphocyte count decreased | 58.68 | 31.18 | 23 | 1031 | 19248 | 29554225 |
Neutrophil count increased | 53.49 | 31.18 | 20 | 1034 | 14722 | 29558751 |
Incision site pain | 51.02 | 31.18 | 12 | 1042 | 1771 | 29571702 |
Platelet count decreased | 38.73 | 31.18 | 31 | 1023 | 104641 | 29468832 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hepatic function abnormal | 111.81 | 23.83 | 50 | 2028 | 64263 | 64432391 |
Incision site pain | 73.13 | 23.83 | 17 | 2061 | 2637 | 64494017 |
Neutrophil count increased | 61.66 | 23.83 | 25 | 2053 | 25149 | 64471505 |
Lymphocyte count decreased | 59.20 | 23.83 | 28 | 2050 | 40671 | 64455983 |
Drug-induced liver injury | 46.43 | 23.83 | 25 | 2053 | 47618 | 64449036 |
Platelet count decreased | 45.77 | 23.83 | 40 | 2038 | 167671 | 64328983 |
White blood cell count increased | 31.62 | 23.83 | 22 | 2056 | 65992 | 64430662 |
Alanine aminotransferase increased | 29.79 | 23.83 | 29 | 2049 | 139002 | 64357652 |
Red blood cells urine positive | 28.36 | 23.83 | 9 | 2069 | 4469 | 64492185 |
Bone marrow failure | 27.81 | 23.83 | 18 | 2060 | 47934 | 64448720 |
Haemoglobin decreased | 26.53 | 23.83 | 32 | 2046 | 195031 | 64301623 |
Blood albumin decreased | 26.09 | 23.83 | 13 | 2065 | 21060 | 64475594 |
Eosinophilic pneumonia chronic | 25.28 | 23.83 | 5 | 2073 | 360 | 64496294 |
Liver injury | 24.46 | 23.83 | 14 | 2064 | 29918 | 64466736 |
Blood urea increased | 24.20 | 23.83 | 16 | 2062 | 44137 | 64452517 |
None
Source | Code | Description |
---|---|---|
ATC | V03AB32 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
CHEBI has role | CHEBI:22586 | antioxidants |
CHEBI has role | CHEBI:23357 | cofactor |
CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
CHEBI has role | CHEBI:77746 | Homo sapiens metabolite |
CHEBI has role | CHEBI:85046 | skin lightening agents |
CHEBI has role | CHEBI:176497 | geroprotectors |
CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
None
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 1.97 | acidic |
pKa2 | 3.3 | acidic |
pKa3 | 9.09 | acidic |
pKa4 | 11.82 | acidic |
pKa5 | 13.85 | acidic |
pKa6 | 9.79 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Glutathione S-transferase kappa 1 | Enzyme | IC50 | 7.70 | CHEMBL |
ID | Source |
---|---|
4020562 | VUID |
N0000148266 | NUI |
D00014 | KEGG_DRUG |
4020562 | VANDF |
C0017817 | UMLSCUI |
CHEBI:16856 | CHEBI |
0P0 | PDB_CHEM_ID |
CHEMBL1543 | ChEMBL_ID |
DB00143 | DRUGBANK_ID |
D005978 | MESH_DESCRIPTOR_UI |
124886 | PUBCHEM_CID |
6737 | IUPHAR_LIGAND_ID |
GAN16C9B8O | UNII |
4890 | RXNORM |
NOCODE | MMSL |
003447 | NDDF |
423272009 | SNOMEDCT_US |
55477000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Bio-7 Serum | HUMAN OTC DRUG LABEL | 2 | 71583-1002 | LIQUID | 3 g | TOPICAL | unapproved drug other | 7 sections |
Bio-7 | HUMAN OTC DRUG LABEL | 2 | 71583-1003 | CREAM | 3.26 g | TOPICAL | unapproved drug other | 7 sections |
HARUTO HANGOVER DEFENCEPATCH | HUMAN OTC DRUG LABEL | 1 | 80094-0001 | PATCH | 1.42 mg | TOPICAL | unapproved drug other | 7 sections |
Deyanling(Cranberry Flavored Collagen Peptide) | HUMAN OTC DRUG LABEL | 3 | 82570-004 | POWDER | 5 g | TOPICAL | unapproved drug other | 8 sections |